家族性低尿钙性高钙血症是误称:24小时尿钙及钙肌酐清除率比值在识别原发性甲状旁腺功能亢进症胚系突变中的局限性
本研究回顾性分析1599例因疑似原发性甲状旁腺功能亢进症行甲状旁腺切除术的患者,发现常规24小时尿钙和钙肌酐清除率比值阈值可能无法可靠识别家族性低尿钙性高钙血症患者。3例携带致病性FHH相关突变的患者其尿钙和比值均高于传统阈值,提示应考虑胚系基因检测。
要点
- 常规尿钙和钙肌酐清除率比值阈值可能漏诊FHH。
- 3例致病性FHH突变患者尿钙均≥240 mg/24h。
- 对无既往血钙正常证据者应考虑胚系基因检测。
核心结论
- 常规24小时尿钙和钙肌酐清除率比值阈值可能无法识别携带致病性FHH相关突变的患者。
研究设计与样本
- 回顾性队列研究,纳入2012年1月至2023年12月单中心因疑似原发性甲状旁腺功能亢进症行初次或再次甲状旁腺切除术的成人患者,共1599例。
主要发现
- 126例(7.8%)尿钙<100 mg/24h,348例(21.7%)100-199 mg/24h,1125例(70.4%)≥200 mg/24h。
- 尿钙<100 mg/24h组尿钙与钙肌酐清除率比值的Spearman相关系数ρ=0.47,≥200 mg/24h组ρ=0.58。
- 254例(15.9%)接受基因检测,20例存在致病性变异或意义未明变异,其中3例携带致病性FHH相关突变(2例CASR,1例AP2S1)。
- 3例致病性FHH突变患者的尿钙/钙肌酐清除率比值分别为326 mg/1.24%、334 mg/1.83%、240 mg/1.00%。
临床怎么用
- 对拟诊原发性甲状旁腺功能亢进症并计划行甲状旁腺切除术、且无既往血钙正常记录或其他获得性高钙血症证据的患者,应考虑胚系基因检测。
局限性
- 本研究为单中心回顾性研究,基因检测仅在15.9%的患者中进行,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Familial hypocalciuric hypercalcemia (FHH) can mimic primary hyperparathyroidism (PHPT), yet commonly used 24-hour urine calcium (UCa) and calcium:creatinine clearance ratio (CCCR) thresholds may not reliably identify patients with FHH before parathyroidectomy. STUDY DESIGN: We retrospectively reviewed a prospectively maintained single-institution database of adults undergoing initial or reoperative parathyroidectomy for presumed PHPT from January 2012 through December 2023. Patients required concurrent 24-hour urine calcium and creatinine measurements and serum calcium and creatinine within 30 days for inclusion in the study. Patients were stratified by UCa (<100, 100-199, ≥200 mg/24h) and CCCR (<1.0%, 1.00-1.99%, ≥2.0%). Spearman's rho assessed correlation between UCa and CCCR. RESULTS: Of 1,599 patients, 126 (7.8%) had UCa <100, 348 (21.7%) had 100-199, and 1,125 (70.4%) had ≥200 mg/24h. CCCR correlated weakly with UCa among patients with UCa <100 (ρ=0.47) and ≥200 (ρ=0.58). Genetic testing was performed in 254 (15.9%) patients; 20 had pathogenic variants or variants of uncertain significance. Three had pathogenic FHH-associated mutations (2 CASR, 1 AP2S1), with UCa/CCCR values of 326 mg/1.24%, 334 mg/1.83%, and 240 mg/1.00%, respectively. CONCLUSIONS: Conventional UCa and CCCR thresholds may fail to identify patients with pathogenic FHH-associated variants. Germline genetic testing should be considered in patients evaluated for PHPT and parathyroidectomy without previously documented normocalcemia or other evidence of acquired hypercalcemia.
引用
- Taylor GA, Dream S, Doffek K, et al. Familial Hypocalciuric Hypercalcemia as a Misnomer: Limitations of 24-Hour Urine Calcium and Calcium:Creatinine Clearance Ratios for Identifying Germline Mutations in Patients with Primary Hyperparathyroidism. J Am Coll Surg. 2026. PMID: 42635369. doi:10.1097/XCS.0000000000002166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。